Paul D. Brown Highlights 3-Fraction SRS Trial in Brain Metastases
Paul D. Brown, Radiation Oncologist at Mayo Clinic, shared a post on X about a paper by Daniella Klebaner et al. published in the International Journal of Radiation Oncology-Biology-Physics:
“Phase 1/2 Dose Escalation 3 Fraction SRS Cavity Resected Brain Met
Authors rec’d based on balance LC and RN:
- Cavity 2-3cm 27-30/3
- Cavity 3-4cm 27/3
- Cavity <3cm High Risk 33/3.”
Giuseppe Minniti, Professor of Radiation Oncology and Chair of the Academic Unit of Radiation Oncology, Department of Radiological Sciences, Oncology, and Anatomical Pathology at Sapienza University, shared this post, adding:
“Thanks for sharing… For cavity > 2 cm we recently found similar control between 3 x 9 Gy and 5 x 6 Gy in 191 patients, with no differences in the risk of symptomatic RN (G2 and 3 < 10%) for V24 (brain less GTV)< 10 cc (3fr) and V30 < 10 cc (5 fr).”
Title: Phase 1/2 Dose Escalation Trial of 3-Fraction Stereotactic Radiosurgery for Resection Cavities from Large Brain Metastases
Authors: Daniella Klebaner, Erqi L. Pollom, Elham Rahimy, Iris C. Gibbs, John R. Adler, Steven D. Chang, Gordon Li, Clara Y.H. Choi, Scott G. Soltys
You can read the Full Article on the International Journal of Radiation Oncology-Biology-Physics.
More posts featuring Paul D. Brown.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023